SHL Medical marks global milestone with 1.5 billion autoinjectors shipped

With 1.5 billion autoinjectors shipped worldwide, SHL Medical celebrates a significant milestone in our journey to enable patients’ independence. This achievement reflects both the scale of our global impact and the trust placed in us by pharmaceutical and biotech partners who continue to inspire our innovation in drug delivery. 

This milestone builds on more than 35 years of experience. Over time, SHL Medical has grown into one of the industry’s leading providers of advanced self-injection systems. Our device solutions, including the widely adopted Molly® platform and the recently introduced Reunite™ autoinjector, have supported the launch of more than 60 combination products across a broad range of therapeutic areas. In 2024 alone, more than 140 million SHL Medical autoinjectors reached patients worldwide. 

“This milestone is not only about scale, but also about the impact on patients who rely on combination products every day,” said Ulrich Faessler, Chairman and CEO of SHL Medical. “Our continued growth is built on the commitment of our people and the confidence of our partners, who count on us to deliver quality, reliability, and innovation at every stage.” 

Our global expansion further demonstrates our commitment to meeting the evolving needs of the pharmaceutical industry. This year, we celebrated the grand opening of our manufacturing facility in South Carolina, USA, and continued preparations for new sites in Zug, Switzerland, and Taoyuan-Nanmei, Taiwan. Together, these investments strengthen our supply chain agility, expand our manufacturing capabilities, and prepare us for the next wave of autoinjector innovation. 

As demand for autoinjectors continues to grow, SHL Medical is investing in sustainable manufacturing, innovative drug delivery technologies, and long-term partnerships, helping bring therapies to patients safely, reliably, and at scale.